Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Protein Kinase Inhibitors
  • TOR Serine-Threonine Kinases

abstract

  • Analysis of outlier cases can facilitate identification of potential biomarkers for targeted agents, and we implicate two genes as candidates for further study in this class of drugs. The previously reported phenomenon of clonal convergence can occur within a targetable pathway which might have implications for biomarker development beyond this disease and this class of agents.

publication date

  • April 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4140619

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-13-2345

PubMed ID

  • 24622468

Additional Document Info

start page

  • 1955

end page

  • 64

volume

  • 20

number

  • 7